Sign in
TerminatedPhase 1

Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI

Key facts

Who runs it
Xemed LLC
Where
Philadelphia, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1
People taking part
9 people enrolled
Started
17 Mar 2023
Ended
28 Feb 2025
Type of study
Interventional, 2 groups
Treatments tested
  • Hyperpolarized xenon MRI
Record updated
20 January 2026
Why it stopped
Regulatory compliance.

Who can take part

Age
18 years to 85 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Patients over 18 years with a diagnosis of non-small lung cancer and planned for a definitive course of radiation therapy
  • Preferred patients will have had successful radiation therapy for a prior lung cancer and developed a secondary lung cancer for which are to be treated
  • Other de-nuovo lung cancer patients planned for radiation therapy with lung heterogeneity from natural co-morbidities (e.g., COPD stage 3+)

Who cannot take part

  • Active drug or alcohol dependence
  • A language, communication, cognitive or behavioral impairment that might interfere with fully informed participation in the study
  • History of uncompensated organ failure (i.e. organ failure that is not stabilized through medical intervention), which will be assessed by the PI
  • Patients less than 18 years old
  • Patients known to be pregnant - a positive pregnancy test will be used to respectively exclude pregnant patients,
  • Any known contraindication to MRI examination
  • Anyone with an implanted metal device
  • Inability to provide informed consent
  • Homelessness or other unstable living situation
  • Claustrophobia
  • Subjects weighting more than 300 pounds
  • Subjects with chest size larger than the bore of MRI machine can accommodate

Where in United States

  • Hospital of the University of PennsylvaniaPhiladelphia, United States

About the trial

What the trial wants to find out

Cancer radiation treatment plans that employ lung functional avoidance methods require 3D maps that differentiate regions of healthy lung function from regions of compromised tissue to deliver sufficient dose to the tumor while preserving as much functioning lung as possible. Hyperpolarized xenon-129 MRI can provide maps of ventilatory function and gas exchange to the bloodstream. Improving treatment plans based on this novel imaging modality could reduce risk or severity of radiation pneumonitis and improve post-treatment quality of life.

The 2 groups in the trial

  • Standard-of-care Radiation Therapy for lung cancer using HXe MRI for diagnosis.Treatment being tested

    Patients with non-small cell lung cancer scheduled for radiation therapy will be voluntarily enrolled in this study, where they will have their lung ventilation and function imaged with hyperpolarized xenon MRI. The 3D HXe images will be used in determining a functional lung avoidance treatment map. However, for this part of the study, subjects will still follow the standard-of-care radiation treatment plan. At 6-month follow up the subjects will be imaged again with HXe to assess lung ventilation and function post-RT compared to baseline (pre-RT). Additionally, standard-of-care lung testing (DLCO, PFT) and quality-of-life questionnaires will be assessed at several time points during the study.

    Treatment: Hyperpolarized xenon MRI

  • Guided Radiation Therapy for lung cancer using HXe MRI for functional lung avoidance and diagnosis.Treatment being tested

    Patients with non-small cell lung cancer scheduled for radiation therapy will be voluntarily enrolled in this study. They will have their lung ventilation and function imaged with hyperpolarized xenon MRI. The 3D HXe images will be used in determining a functional lung avoidance treatment map. Patients will follow radiation therapy optimized for functional lung avoidance. At 6-month follow up the subjects will be imaged again with HXe to assess lung ventilation and function post-RT compared to baseline (pre-RT). Additionally, standard-of-care lung testing (DLCO, PFT) and quality-of-life questionnaires will be assessed at several time points during the study.

    Treatment: Hyperpolarized xenon MRI

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
20 January 2026